INMED PHARMACEUTICALS INC. Foreign Currency Transaction Gain (Loss), before Tax
INMED PHARMACEUTICALS INC. (INM) reported Foreign Currency Transaction Gain (Loss), before Tax of -$58.01 thousand for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was $4.02K, a 81.85% decline year-over-year.
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was -$23.17K.
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was $18.14K.
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was -$56.99K, a 395.15% decline year-over-year.
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), before tax for fiscal 2022 was -$117.55K.
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), before tax for fiscal 2021 was -$163.10K, a 298.45% decline from fiscal 2020.
- INMED PHARMACEUTICALS INC. foreign currency transaction gain (loss), before tax for fiscal 2020 was $82.19K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.02K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | -$19.15K derived: sum of 2 quarters · filed 2026-09-09 | -$1.01K derived: sum of 3 quarters · filed 2026-09-09 | -$58.01K S-4/A · filed 2026-09-09 |
| 2026-03-31 | -$23.17K S-4 · filed 2026-07-02 | -$5.03K derived: sum of 2 quarters · filed 2026-07-02 | -$62.03K S-4 · filed 2026-07-02 | -$39.89K derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-12-31 | $18.14K 10-Q · filed 2026-02-11 | -$38.86K 10-Q · filed 2026-02-11 | -$16.72K derived: sum of 3 quarters · filed 2026-09-09 | -$38.89K derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-09-30 | -$56.99K 10-Q · filed 2025-11-06 | -$34.86K derived: sum of 2 quarters · filed 2026-09-09 | -$57.02K derived: sum of 3 quarters · filed 2026-09-09 | -$104.78K derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-06-30 | $22.14K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | -$28.00 derived: sum of 2 quarters · filed 2026-09-09 | -$47.78K derived: sum of 3 quarters · filed 2026-09-09 | -$28.47K S-4/A · filed 2026-09-09 |
| 2025-03-31 | -$22.16K S-4 · filed 2026-07-02 | -$69.92K derived: sum of 2 quarters · filed 2026-07-02 | -$50.61K S-4 · filed 2026-07-02 | -$75.81K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-12-31 | -$47.75K 10-Q · filed 2026-02-11 | -$28.44K 10-Q · filed 2026-02-11 | -$53.65K derived: sum of 3 quarters · filed 2026-07-02 | -$101.80K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-09-30 | $19.31K 10-Q · filed 2025-11-06 | -$5.89K derived: sum of 2 quarters · filed 2026-07-02 | -$54.05K derived: sum of 3 quarters · filed 2026-07-02 | $5.85K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-06-30 | -$25.20K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | -$73.36K derived: sum of 2 quarters · filed 2026-07-02 | -$13.46K derived: sum of 3 quarters · filed 2026-07-02 | -$61.92K S-4 · filed 2026-07-02 |
| 2024-03-31 | -$48.16K 10-Q · filed 2025-05-12 | $11.74K derived: sum of 2 quarters · filed 2025-05-12 | -$36.72K 10-Q · filed 2025-05-12 | |
| 2023-12-31 | $59.90K 10-Q · filed 2025-02-12 | $11.44K 10-Q · filed 2025-02-12 | ||
| 2023-09-30 | -$48.46K 10-Q · filed 2023-11-14 | |||
| 2022-09-30 | -$96.79K 10-Q · filed 2023-11-14 | -$166.23K derived: sum of 2 quarters · filed 2023-11-14 | -$133.24K derived: sum of 3 quarters · filed 2023-11-14 | -$130.23K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$69.44K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | -$36.45K derived: sum of 2 quarters · filed 2022-09-23 | -$33.44K derived: sum of 3 quarters · filed 2022-09-23 | -$117.55K 10-K · filed 2022-09-23 |
| 2022-03-31 | $33.00K 10-Q · filed 2022-05-13 | $36.00K derived: sum of 2 quarters · filed 2022-05-13 | -$48.11K 10-Q · filed 2022-05-13 | -$5.39K derived: sum of 4 quarters · filed 2022-09-23 |
| 2021-12-31 | $3.01K 10-Q · filed 2022-02-14 | -$81.11K 10-Q · filed 2022-02-14 | -$38.38K derived: sum of 3 quarters · filed 2022-09-23 | -$9.91K derived: sum of 4 quarters · filed 2022-09-23 |
| 2021-09-30 | -$84.11K 10-Q · filed 2021-11-10 | -$41.39K derived: sum of 2 quarters · filed 2022-09-23 | -$12.92K derived: sum of 3 quarters · filed 2022-09-23 | -$207.71K derived: sum of 4 quarters · filed 2022-09-23 |
| 2021-06-30 | $42.72K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | $71.19K derived: sum of 2 quarters · filed 2022-09-23 | -$123.60K derived: sum of 3 quarters · filed 2022-09-23 | -$163.10K 10-K · filed 2022-09-23 |
| 2021-03-31 | $28.47K 10-Q · filed 2022-05-13 | -$166.32K derived: sum of 2 quarters · filed 2022-05-13 | -$205.82K 10-Q · filed 2022-05-13 | -$266.31K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$194.79K 10-Q · filed 2022-02-14 | -$234.29K 10-Q · filed 2022-02-14 | -$294.78K derived: sum of 3 quarters · filed 2022-02-14 | -$140.85K derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | -$39.50K 10-Q · filed 2021-11-10 | -$99.99K derived: sum of 2 quarters · filed 2021-11-10 | $53.94K derived: sum of 3 quarters · filed 2021-11-10 | $26.76K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$60.49K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | $93.44K derived: sum of 2 quarters · filed 2021-09-24 | $66.25K derived: sum of 3 quarters · filed 2021-09-24 | $82.19K 10-K · filed 2021-09-24 |
| 2020-03-31 | $153.93K 10-Q · filed 2021-05-13 | $126.75K derived: sum of 2 quarters · filed 2021-05-13 | $142.68K 10-Q · filed 2021-05-13 | |
| 2019-12-31 | -$27.18K 10-Q · filed 2021-02-11 | -$11.25K 10-Q · filed 2021-02-11 | ||
| 2019-09-30 | $15.93K 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |